BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, March 25, 2026
See today's BioWorld
Home
» Other news to note for Jan. 4, 2022
To read the full article
sign up for free
or
sign in
.
Other news to note for Jan. 4, 2022
Jan. 4, 2022
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Advicenne, Affiris, Allarity, Amyris, Arbor, Aveo, Astrazeneca, Bayer, Biogen, Biologics of Jemincare, Biomx, Biorestorative, Cognition, Cumberland, Evotec, Frontier, Genocea, Genprex, Green Cross, Hansa, Hoth, Immunitybio, Ionis, J&J, Kyverna, Kyowa, Merck, Oncoheroes, Ovid, Prometheus, Rivaara, Santhera, Sperogenix, Soligenix, TCR2, Tonix, Vaxil.
BioWorld
Briefs
Other news to note
Coronavirus